Study: Drugs reprogram genes in breast tumors to prevent endocrine resistance

IMAGE: University of Illinois food science and human nutrition professor and her team found in a new study that targeting estrogen receptor-positive breast tumors with the XPO1 antagonist selinexor and the… view more  CHAMPAIGN, Ill. — Treating breast tumors with two cancer drugs simultaneously may prevent endocrine resistance by attacking the disease along two separate gene…

Details

Advances in cryo-EM materials may aid cancer and biomedical research

IMAGE: The Kelly Lab, in collaboration with Protochips, Inc., has developed new custom-designed substrates (cryo-ChipsTM ) for use in cryo-Electron Microscopy. These substrates enabled structural studies of mutated proteins formed in… view more  Credit: Deb Kelly / Penn State Cryogenic-Electron Microscopy (cryo-EM) has been a game changer in the field of medical research, but the substrate,…

Details

Researchers devise a progression risk-based classification for patients with AWM

IMAGE: Mark Bustoros, MD view more  Credit: Dana-Farber Cancer Institute By analyzing data from hundreds of patients with asymptomatic Waldenström macroglobulinemia (AWM), researchers at Dana-Farber Cancer Institute have devised a risk model for determining whether patients with AWM have a low, intermediate, or high risk of developing symptomatic Waldenström macroglobulinemia (WM), which requires chemotherapy treatment. Waldenström…

Details

Insilico to present at the Health Horizons Future Healthcare Forum

IMAGE: Alex Zhavoronkov, Ph.D., Founder and CEO of Insilico Medicine, to present at the Health Horizons Future Healthcare Forum in London, June 26-27 view more  Credit: Insilico Medicine Tuesday, April 23, 2019 – Insilico Medicine, a biotech company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in…

Details